Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Cindy Kapinos

Nurse Practitioner, Acute Care Richmond, VA Nurse Practitioner

NPI 1235579335 CMS profile 10469200

7001 Forest Ave Ste 103, Richmond, VA 23230

Open in the dashboard

General payments

$5,298

279 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Cindy Kapinos of Richmond, VA is reported in the CMS Open Payments database as having received $5,298 across 279 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,728 84
2022 General $1,869 101
2021 General $1,701 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cindy Kapinos
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Cindy Kapinos were reported at $0. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Cindy Kapinos Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,701 $123 $38–$327 $132
2022 $1,869 $130 $44–$369 $149
2023 $1,728 $144 $49–$410 $160
2024 $0 $146 $48–$433 $164
2025 $0 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Daiichi Sankyo Inc. $665 55 payments
  2. AstraZeneca Pharmaceuticals LP $500 27 payments
  3. Novartis Pharmaceuticals Corporation $412 21 payments
  4. Eisai Inc. $370 17 payments
  5. Janssen Biotech, Inc. $241 12 payments
  6. Incyte Corporation $234 12 payments
  7. Ipsen Biopharmaceuticals, Inc $180 6 payments
  8. Taiho Oncology, Inc. $174 7 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $172 8 payments
  10. E.R. Squibb & Sons, L.L.C. $162 8 payments
  11. Other $2,188 106 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $5,298 279 payments
Products named General payments · program years 2021–2023
  1. INJECTAFER $490 50 payments
  2. Lenvima $370 17 payments
  3. KISQALI $233 12 payments
  4. JAKAFI $193 10 payments
  5. ENHERTU $175 5 payments
  6. Lonsurf $174 7 payments
  7. FEMARA $171 9 payments
  8. CALQUENCE $166 8 payments
  9. LYNPARZA $161 9 payments
  10. DARZALEX $161 8 payments
  11. Other $4,455 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record